Novartis to revise product information in the European Union for high blood pressure drug Rasilez®
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
List view / Grid view
News
GSK receives positive opinion in Europe from the CHMP for Nimenrix®
17 February 2012 | By GlaxoSmithKline
The EMA's CHMP has issued a positive opinion recommending marketing authorisation for Nimenrix® (MenACWY-TT)...
CHMP recommends approval of BYETTA® for use with basal insulin
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
Abbott receives positive opinion for HUMIRA® in Ulcerative Colitis from EMA’s CHMP
17 February 2012 | By Abbott
Positive opinion based on supporting data from two Phase III clinical studies...
Pfizer and Hisun announce progress on potential joint venture to increase access to high quality branded generic medicines
17 February 2012 | By Pfizer
The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies...
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
16 February 2012 | By GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib)...
Stuart Grant appointed Patheon’s Executive Vice President, Chief Financial Officer
Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Stuart Grant has been appointed Patheon's Executive Vice President, Chief Financial Officer. Mr. Grant comes to Patheon following an accomplished career with increasing levels of responsibility in finance for several…
FDA accepts Pfizer’s New Drug Application for Tafamidis Meglumine
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...
Amgen and Micromet announce early termination of HSR waiting period for Amgen’s acquisition of Micromet
15 February 2012 | By Amgen
Amgen and Micromet entered into a Merger Agreement...
Merck establishes joint venture with Supera Farma
15 February 2012 | By Merck
New Brazilian joint venture to combine local and global commercial expertise...
Amgen names Michael Severino, M.D., Senior VP, Global Development and Corporate Chief Medical Officer
14 February 2012 | By Amgen
"Mike brings broad experience and immense expertise to his new role..."
Biogen Idec to acquire Stromedix
14 February 2012 | By Biogen Idec
Biogen Idec and Stromedix, Inc. announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc...
Study Shows Abbott’s Tacrolimus Assay Demonstrates Consistent Organ Transplant Drug Monitoring
13 February 2012 | By Abbott
Accurate and precise lab-to-lab monitoring is essential for long-term transplant success...
FDA approves ZIOPTAN™ (tafluprost ophthalmic solution)
13 February 2012 | By Merck
ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution...
U.S. FDA grants Priority Review for Truvada® for reducing the risk of acquiring HIV infection
13 February 2012 | By Gilead Sciences Inc
The U.S. FDA has granted a six-month Priority Review for once-daily Truvada®...
